Osimertinib Dose Reduction Does Not Compromise OS in EGFR-Mutated Metastatic NSCLC
“Reducing osimertinib dose in the first-line treatment of EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) patients due to the occurrence of adverse events has no impact on overall survival (OS), according to research published in Lung Cancer.”
Lung Cancer in the Incarcerated Population: A Narrative Review
“While the literature is limited, existing studies indicate that lung cancer has a higher prevalence, is diagnosed at more advanced stages, and carries a higher mortality among incarcerated individuals compared to non-incarcerated individuals. Although lung cancer screening is recommended based on eligibility criteria for the general population, there is a paucity of data on how screening is implemented in carceral settings, and the existing studies suggest that even eligible individuals with significant smoking history often do not undergo lung cancer screening. Furthermore, the literature provides minimal insight into lung cancer treatment for incarcerated patients.”
Experts Call for Expanded Lung Cancer Screening Eligibility Criteria
“Key Takeaways: Technological advances and multidisciplinary collaboration are essential for improving lung cancer screening and treatment strategies. Screening guidelines vary, with some models considering factors beyond smoking history, such as family history and personal cancer history.”
Radiologists, rad oncologists and thoracic surgeons rail against lung cancer screening misinformation
“Radiologists, radiation oncologists and thoracic surgeons are speaking out against lung cancer screening misinformation, spread through recently published scientific papers. Medical societies representing all three specialties issued a joint statement on Tuesday, criticizing studies claiming such scans pose potential risk of downstream complications, false positives, and dangerous radiation harm. They contend that many of these investigations are based on “substantial methodological flaws that contribute to the propagation of misinformation.””
Pain Intensity Drives Catastrophizing in Early-Stage Lung Cancer Recovery After Surgery
“For patients recovering from lung cancer surgery, pain is more than a symptom to be measured and managed because thoughts, emotions, and support systems can strongly influence how pain is perceived. New research highlights the prevalence of pain catastrophizing during the postoperative recovery period, underscoring the psychologic and social factors that shape the pain experiences of patients after surgery.”
Drug-Induced Pneumonitis: The Risk Behind New Cancer Therapies
“Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, immunotherapies, and emerging antibody—drug conjugates are helping many patients live longer—and live well. But these gains may come with risks, including one called drug-induced pneumonitis, an inflammatory reaction in the lungs that ranges from mild to life-threatening.”
For lung cancer patients, smoking history may help pinpoint best treatment
“Detailed information about the current and former smoking habits of patients with non-small cell lung cancer (NSCLC) can shed light on the best way to treat them—whether with a combination of chemotherapy and immunotherapy, or with immunotherapy alone, according to new research from Harvard T.H. Chan School of Public Health.”
A study analyses which lung cancer subtypes are associated with different air pollutants
“A study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by “la Caixa” Foundation, in collaboration with the American Cancer Society (ACS), analysed the relationship between different air pollutants and the main subtypes of lung cancer. The results were published in Environmental Pollution.”
Newly discovered survival pathway explains stubborn EGFR-driven lung cancers
“Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene called EGFR (epidermal growth factor receptor). In a study published in Science Advances, the researchers revealed a previously unknown survival mechanism and demonstrated that disrupting it can shrink tumors in laboratory models.”
Firmonertinib Demonstrates Promise in EGFR+ Advanced/Metastatic NSCLC
“Double-dose firmonertinib yielded promising efficacy and a manageable safety profile in a small cohort of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR L858R mutations, according to data from the phase 2 FIRM study (ChiCTR2200060897) published in Nature Communications.”
